{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:03:00Z","timestamp":1760821380672,"version":"3.41.2"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Peripheral T-cell lymphoma (PTCL) is a rare and heterogenous hematologic malignancy with poor prognosis especially in elderly and frail patients who are not eligible for intensive treatment. The resulting palliative setting necessitates tolerable but effective schedules for outpatient treatment. TEPIP is a locally developed, all-oral low-dose regimen comprising trofosfamide, etoposide, procarbazine, idarubicin, and prednisolone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this observational retrospective, single-center study, the safety and efficacy of TEPIP was evaluated in 12 patients (pts.) with PTCL treated at the University Medical Center Regensburg between 2010 and 2022. The endpoints were overall response rate (ORR) and overall survival (OS), and adverse events were individually reported according to the Common Terminology Criteria for Adverse Events (CTCAE) criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The enrolled cohort was characterized by advanced age (median 70 years), extensive disease (100% Ann Arbor \u2265stage 3), and poor prognosis (75% high\/high-intermediate international prognostic index). The most common subtype was angioimmunoblastic T-cell lymphoma (8\/12), and 11\/12 patients had relapsed or refractory disease at TEPIP onset with a median of 1.5 prior treatment regimens. After a median of 2.5 TEPIP cycles (total of 83 cycles), the ORR was 42% (complete remission 25%), and the OS reached a median of 185 days. Any grade of adverse event (AE) occurred in 8\/12 patients, with four patients showing AE \u2265CTCAE grade 3 (33%), and the AEs were mainly non-hematological.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>TEPIP demonstrated competitive efficacy with a tolerable safety profile in a highly palliative cohort of patients with difficult-to-treat PTCL. The all-oral application, which makes outpatient treatment possible, is particularly noteworthy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1177330","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T04:24:56Z","timestamp":1685075096000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Matthias A.","family":"Fante","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis C.","family":"Harrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Zartner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"L\u00fcke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Menhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albrecht","family":"Reichle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Herr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Vogelhuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Heudobler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.852987","article-title":"All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in Relapsed\/Refractory patients with aggressive b-cell lymphoma","volume":"12","author":"Fante","year":"2022","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the world health organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357","article-title":"2016 US Lymphoid malignancy statistics by world health organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/623924","article-title":"A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma","volume":"2011","author":"Abouyabis","year":"2011","journal-title":"ISRN Hematol"},{"key":"B6","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-hodgkin's lymphomas. groupe d'Etudes des lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin lymphoma study group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish lymphoma registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000500666","article-title":"Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE registry","volume":"143","author":"Lansigan","year":"2020","journal-title":"Acta Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, international T-cell project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.5045\/br.2017.52.4.270","article-title":"Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma","volume":"52","author":"Choi","year":"2017","journal-title":"Blood Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25463","article-title":"Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry","volume":"94","author":"Stuver","year":"2019","journal-title":"Am J Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study","volume":"134","author":"O'Connor","year":"2019","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.12.039","article-title":"Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance","volume":"358","author":"Kareva","year":"2015","journal-title":"Cancer Lett"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/bies.950130106","article-title":"Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents","volume":"13","author":"Kerbel","year":"1991","journal-title":"Bioessays"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI8829","article-title":"Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity","volume":"105","author":"Klement","year":"2000","journal-title":"J Clin Invest"},{"key":"B23","article-title":"Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts","volume":"8","author":"Klement","year":"2002","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04172-3","article-title":"All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma","volume":"86","author":"Cox","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08367.x","article-title":"Continuous oral cyclophosphamide and prednisolone as a valuable treatment option for peripheral T cell lymphoma","volume":"152","author":"Tucci","year":"2011","journal-title":"Br J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1055484","article-title":"Remission of an extensively pre-treated relapsing\/refractory ALK-positive anaplastic large cell lymphoma following metronomic therapy","volume":"57","author":"Yuan","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23422","article-title":"Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-c) oral combination chemotherapy regimen for recurring\/refractory lymphoma: low-dose metronomic, multidrug therapy","volume":"112","author":"Coleman","year":"2008","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"JCO"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e672","DOI":"10.1097\/HS9.0000000000000672","article-title":"Prolonged remissions after nivolumab plus Gemcitabine\/Oxaliplatin in Relapsed\/Refractory T-cell lymphoma","volume":"6","author":"Houot","year":"2022","journal-title":"Hemasphere"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3109\/02841869109091828","article-title":"Trofosfamide in non-hodgkin's lymphoma. a phase II study","volume":"30","author":"Wist","year":"1991","journal-title":"Acta Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000040053","article-title":"Trofosfamide as salvage therapy for anaplastic large cell lymphoma relapsing after high-dose chemotherapy","volume":"43","author":"Andersson","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s0025-7125(16)31847-8","article-title":"Chemotherapy of the non-hodgkin's lymphomas","volume":"60","author":"Pasmantier","year":"1976","journal-title":"Med Clin North Am"},{"key":"B33","doi-asserted-by":"publisher","first-page":"14369","DOI":"10.1038\/s41598-022-18540-x","article-title":"Comparison of CEAC, BEAM and IEAC conditioning regimens followed by autologous stem cell transplantation in peripheral T-cell lymphoma patients","volume":"12","author":"Xiong","year":"2022","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01571-8","article-title":"Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma","volume":"36","author":"Wong","year":"2022","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy","volume":"11","author":"Andr\u00e9","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.03.011","article-title":"Metronomic chemotherapy: direct targeting of cancer cells after all","volume":"3","author":"Andr\u00e9","year":"2017","journal-title":"Trends Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.64","article-title":"Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect","volume":"13","author":"Bocci","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11034","article-title":"Therapy-related leukemia and myelodysplasia: susceptibility and incidence","volume":"92","author":"Leone","year":"2007","journal-title":"Haematologica"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-512657","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin study group","volume":"123","author":"Eichenauer","year":"2014","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1177330\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T04:25:01Z","timestamp":1685075101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1177330\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":43,"alternative-id":["10.3389\/fonc.2023.1177330"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1177330","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"article-number":"1177330"}}